The prevalence of human papillomavirus vaccination among racial and ethnic minority adolescents during the COVID-19 pandemic.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
31 08 2023
31 08 2023
Historique:
received:
30
05
2023
revised:
03
07
2023
accepted:
24
08
2023
medline:
27
9
2023
pubmed:
31
8
2023
entrez:
31
8
2023
Statut:
ppublish
Résumé
Human papillomavirus (HPV) vaccination among adolescents has steadily improved over the past several years. However, research conducted to determine whether the COVID-19 pandemic disrupted this positive trend in HPV vaccine initiation among racial and ethnic minority adolescents is limited. Therefore, this study was conducted to determine if the COVID-19 pandemic and the resulting changes in the US health-care sector affected the increasing HPV vaccine initiation among non-Hispanic Black and Hispanic adolescents aged 13-17 years. Using a cross-sectional design to examine data from the National Immunization Survey-Teen (2019-2021), logistic regression and moderation analysis were used to model race-specific variations in HPV vaccine initiation (n = 49 031). Two-sided P values of up to .05 were considered statistically significant. Hispanic (adjusted odds ratio [AOR] = 1.35, 95% confidence interval [CI] = 1.16 to 1.57) and non-Hispanic Black (AOR = 1.29, 95% CI = 1.10 to 1.51) adolescents had higher odds of HPV vaccine initiation than did non-Hispanic White adolescents. Additionally, the odds of HPV vaccine initiation were higher in 2021 (AOR = 1.22, 95% CI = 1.08 to 1.38) than in 2019. Other variables-age, region, sex, insurance status, and poverty status-were also associated with HPV vaccine initiation. These findings demonstrate that during the COVID-19 pandemic, racial and ethnic minorities had higher odds of receiving the HPV vaccine. Therefore, more research of the impact of the pandemic on HPV vaccine initiation among non-Hispanic White and racial and ethnic minority adolescents is needed.
Sections du résumé
BACKGROUND
Human papillomavirus (HPV) vaccination among adolescents has steadily improved over the past several years. However, research conducted to determine whether the COVID-19 pandemic disrupted this positive trend in HPV vaccine initiation among racial and ethnic minority adolescents is limited. Therefore, this study was conducted to determine if the COVID-19 pandemic and the resulting changes in the US health-care sector affected the increasing HPV vaccine initiation among non-Hispanic Black and Hispanic adolescents aged 13-17 years.
METHODS
Using a cross-sectional design to examine data from the National Immunization Survey-Teen (2019-2021), logistic regression and moderation analysis were used to model race-specific variations in HPV vaccine initiation (n = 49 031). Two-sided P values of up to .05 were considered statistically significant.
RESULTS
Hispanic (adjusted odds ratio [AOR] = 1.35, 95% confidence interval [CI] = 1.16 to 1.57) and non-Hispanic Black (AOR = 1.29, 95% CI = 1.10 to 1.51) adolescents had higher odds of HPV vaccine initiation than did non-Hispanic White adolescents. Additionally, the odds of HPV vaccine initiation were higher in 2021 (AOR = 1.22, 95% CI = 1.08 to 1.38) than in 2019. Other variables-age, region, sex, insurance status, and poverty status-were also associated with HPV vaccine initiation.
CONCLUSION
These findings demonstrate that during the COVID-19 pandemic, racial and ethnic minorities had higher odds of receiving the HPV vaccine. Therefore, more research of the impact of the pandemic on HPV vaccine initiation among non-Hispanic White and racial and ethnic minority adolescents is needed.
Identifiants
pubmed: 37651597
pii: 7254483
doi: 10.1093/jncics/pkad065
pmc: PMC10521629
pii:
doi:
Substances chimiques
Papillomavirus Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
J Gen Intern Med. 2022 Apr;37(5):1191-1197
pubmed: 35112280
Vaccine. 2018 Jun 7;36(24):3498-3504
pubmed: 29752025
Rev Obstet Gynecol. 2008 Winter;1(1):2-10
pubmed: 18701931
MMWR Morb Mortal Wkly Rep. 2020 Aug 21;69(33):1109-1116
pubmed: 32817598
J Adolesc Health. 2020 Nov;67(5):633-634
pubmed: 32933839
Cancer Epidemiol Biomarkers Prev. 2020 Jul;29(7):1458-1467
pubmed: 32345710
Public Health. 2017 Jan;142:167-176
pubmed: 27592005
MMWR Morb Mortal Wkly Rep. 2021 Sep 03;70(35):1183-1190
pubmed: 34473682
J Vocat Behav. 2020 Jun;119:103439
pubmed: 32390658
Vaccines (Basel). 2022 Feb 24;10(3):
pubmed: 35334983
Hum Vaccin Immunother. 2019;15(1):146-155
pubmed: 30148974
J Public Health Manag Pract. 2022 Jan-Feb 01;28(1):E299-E306
pubmed: 33729198
MMWR Morb Mortal Wkly Rep. 2019 Aug 23;68(33):718-723
pubmed: 31437143
MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):350-354
pubmed: 33705364
R Soc Open Sci. 2021 Aug 4;8(8):210227
pubmed: 34386248
Vaccine. 2020 Aug 27;38(38):5963-5965
pubmed: 32709431
Am J Public Health. 2021 Feb;111(2):286-292
pubmed: 33351662
JNCI Cancer Spectr. 2021 Mar 02;5(2):pkab011
pubmed: 33748668
J Community Health. 2023 Aug;48(4):678-686
pubmed: 36920709
Clin Infect Dis. 2021 Feb 16;72(4):703-706
pubmed: 32562416
Vaccine. 2019 Jan 21;37(4):595-601
pubmed: 30580838
J Med Syst. 2020 Jun 15;44(7):132
pubmed: 32542571
Soc Sci Med. 2013 Apr;82:115-25
pubmed: 23337830
Virology. 2013 Oct;445(1-2):2-10
pubmed: 23683837
MMWR Morb Mortal Wkly Rep. 2020 Oct 23;69(42):1517-1521
pubmed: 33090984
JAMA Otolaryngol Head Neck Surg. 2021 Mar 1;147(3):287-295
pubmed: 33443539
Health Psychol. 2016 Apr;35(4):407-11
pubmed: 27018733
Hum Vaccin Immunother. 2020 Mar 3;16(3):554-561
pubmed: 31662024
Prev Med. 2019 Jun;123:197-203
pubmed: 30930259